Protective Order Forecloses Participation of Litigation Counsel in Motion to Amend Process Before the PTAB

May 17, 2024

Reading Time : 3 min

In keeping with precedent, a judge in the District of Delaware issued an oral order restricting the extent of permissible activities for litigation counsel before the Patent Trial and Appeal Board. The order resolved a protective order dispute over the proper scope of a patent prosecution bar, concluding that litigation counsel that had access to confidential information is restricted from participating in the motion to amend process in an IPR.

Plaintiffs brought an action in the District of Delaware alleging that defendants infringed several patents. Defendants responded by filing IPR petitions at the PTAB challenging the patentability of each asserted patent. Before discovery commenced in the district court litigation, the parties met-and-conferred on a protective order. During those negotiations, a dispute arose over the scope of a proposed prosecution bar. While both parties agreed that litigation counsel that had access to defendants’ confidential information could participate generally in the IPRs, they disagreed over counsels’ involvement in the IPR motion to amend process. Plaintiffs’ proposed protective order language made clear that arguing the patentability of claims presented in a motion to amend should not be barred. Defendants’ proposed language, on the other hand, prevented litigation counsel from participating in any way in a motion to amend, including drafting a motion to amend and arguing the patentability of the amended claims.

In advocating for their proposed protective order language, plaintiffs pointed out that claims in an IPR can only be narrowed. Therefore, arguing the patentability of amended claims presents no more risk of inadvertent disclosure of confidential information than arguing the patentability of original claims, which defendants’ proposal would permit. Plaintiffs further contended that defendants’ proposed language banning litigation counsel from participating in motions to amend would severely prejudice plaintiffs by depriving them of their choice of counsel, resulting in duplication of efforts and increased costs.

Defendants disagreed and argued that allowing litigation counsel with access to defendants’ confidential information to participate in the motion to amend process would subject even the most scrupulous counsel to the risk of influencing the scope of proposed amended claims with that confidential information in mind. That risk, defendants claimed, is further exacerbated by the fact that (during the motion to amend process) the patent owner can change the scope of the claims after receiving preliminary guidance from the board. According to defendants, in arguing a motion to amend, the patent owner may advance arguments that affect the claims’ scope, including via claim construction or disclaimer. Because patent owners can potentially obtain new claims with different scope, in defendants’ view, a bright-line rule prohibiting litigation counsel that received confidential information from participating in motions to amend is necessary. Finally, defendants argued that plaintiffs would suffer no prejudice by the ban because they could select counsel from the same law firm as litigation counsel to argue motions to amend.

Ultimately, the court adopted defendants’ language and in doing so noted that it is consistent with the “balanced approach” taken previously in the District of Delaware that allowed litigation counsel to participate in IPRs except as to activities related to amending claims. The court further explained that although claims can only be narrowed in an IPR, there is still a risk that the patent owner could use confidential information to craft claims that avoid prior art but still cover defendants’ product. Moreover, the court emphasized that plaintiffs failed to explain how their litigation counsel could draft or argue a motion to amend without discussing the claim amendments with the patent prosecutors. The court concluded that allowing even limited involvement in the motion to amend process “could defeat the purpose of implementing the prosecution bar in the first place.”

Practice Tip: In negotiating the terms of a protective order, parties should be intimately familiar with precedent in the jurisdiction in question. If appropriate, defendants should consider seeking to include language that unambiguously restricts plaintiff’s litigation counsel that had access to defendant’s confidential information from working on motions to amend in any co-pending IPR. Plaintiffs, on the other hand, should consider shielding at least one attorney on their team from defendant’s confidential information to ensure that the attorney can participate in a motion to amend in the IPR, including by drafting and arguing the motion to amend.

Aerin Med. Inc., et al. v. Neurent Med. Inc., et al., Case No. 1-23-cv-00756, D.I. 66 (D. Del. May 8, 2024) (Fallon, J.).

Share This Insight

Previous Entries

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.